Effects of pegylated interferon-α-2a monotherapy on growth in Japanese children with chronic hepatitis C

Hepatology Research

Volumn 44, Issue 3, 2014, Pages 251-258

  Tsunoda, Tomoyuki ^a   Inui, Ayano ^a   Kawamoto, Manari ^a   Sogo, Tsuyoshi ^a   Komatsu, Haruki ^b   Fujisawa, Tomoo ^a  

^a SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

^b TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

Author keywords

Growth velocity; Height; Mother to infant transmission; Weight; Z score

Indexed keywords

PEGINTERFERON ALPHA2A;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CHILD GROWTH; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GROWTH RATE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; VERTICAL TRANSMISSION;

EID: 84885630270     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12118     Document Type: Article

References (24)

1. González-Peralta RP, Langham MR Jr, Andres JM etal. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009; 48: 630-635.
2. Tsunoda T, Inui A, Etani Y etal. Efficacy of pegylated interferon-α2a monotherapy in Japanese children with chronic hepatitis C. Hepatol Res 2011; 41: 399-404.
3. Tajiri H, Inui A, Kiyohara Y etal. Peginterferon alpha-2b and riba for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology. Eur J Gastroenterol Hepatol 2009; 21: 1256-1260.
4. Shiraki K, Morishima T, Terasawa S, Koike M, Fujisawa T, Tajiri H, OPC-18 Study Group. Long-term virological response and growth rate of children with chronic hepatitis C who received natural interferon-α. Eur J Pediatr 2002; 161: 629-630.
5. Komatsu H, Inui A, Tsunoda T, Sogo T, Fujisawa T. Association between an IL-28B genetic polymorphism and the efficacy of the response-guided pegylated interferon therapy in children with chronic hepatic C infection. Hepatol Res 2012. doi: 10.1111/j.1872-034X.2012.01087.x.
6. Bossa P, Poynard T, the French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. Hepatology 1996; 24: 289-293.
7. Suwa S, Tachibana K, Maesaka H, Tanaka T, Yokoya S. Longitudinal standards for height and height velocity for Japanese children from birth to maturity. Clin Pediatr Endocrinol 1992; 1: 5-13.
8. Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series No.854. Geneva: World Health Organization, 1995.
9. Ministry of Health and Welfare. Preparation of standard height/weight table of fiscal year 2000 version. Foundation for Growth Science Annual Report no. 25. 2000.
10. Jonas MM, Balistreri W, Gonzalez-Peralta RP etal. Peginterferon for chronic hepatitis C in children affects growth and body composition: results from pediatric study of hepatitis C (PEDS-C) trial. Hepatology 2012; 56: 523-531.
11. Wirth S, Ribes-Koninckx C, Calzado MA etal. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501-507.
12. Kelly D, Haber B, Gonzalez-Peralta RP etal. Sustained virologic response to interferon alfa-2b plus ribavirin predicts long-term clearance of HCV in pediatric patients at 5-year follow-up 2008. 43rd annual meeting of the European association for the study of the liver; April 23-27, 2008; Milan, Italy.
13. Komatsu H, Fujisawa T, Inui A etal. Efficacy of interferon in treating chronic hepatitis C in children with a history of acute leukemia. Blood 1996; 87: 4072-4075.
14. Ferenci P, Laferl H, Scherzer TM etal. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010; 138: 503-512.
15. Sanches-Tapias JM, Diago M, Escartin P etal. Peginterferon-alfa 2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-460.
16. Oze T, Hiramatsu N, Yakushijin T etal. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. J Viral Hepat 2009; 16: 578-585.
17. Del Monte P, Bernasconi D, De Conca V etal. Endocrine evaluation in patients treated with interferon-alpha for chronic hepatitis C. Horm Res 1995; 44: 105-109.
18. Plöckinger U, Krüger D, Bergk A, Weich V, Wiedenmann B, Berg T. Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. Am J Gastroenterol 2007; 102: 2724-2731.
19. Picardi A, Gentilucci UV, Zardi EM etal. TNF-alpha and growth hormone resistance in patients with chronic liver disease. J Interferon Cytokine Res 2003; 23: 229-235.
20. Arron JR, Choi Y. Bone versus immune system. Nature 2000; 408: 535-536.
21. Martensson K, Chrysis D, Savedah L. Interleukin-1β and TNF-α act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 2004; 19: 1805-1812.
22. Gottrand F, Michaud L, Guimber D etal. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr 1996; 155: 1031-1034.
23. Rodrigue JR, Balistreri W, Haber B etal. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009; 48: 341-347.
24. Foster G, Goldin R, Thomas H. Chronic hepatitis C infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-212.